February 2003

Contents

Editorial

• Volume 4 Number 1 January/February 2003

Conference reports

• 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow, UK

• Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP

• An overview of the conference

• Pharmacokinetic evaluation of tenofovir and enteric-coated ddI

• The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates

• Promising data regarding DermaVir for therapeutic vaccine

• Enfuvirtide (T-20): predicting success and modelling survival benefits

• Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz

• Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients

• Safety profile of tenofovir in treatment-experienced patients

Antiretrovirals

• Roche and Trimeris able to make enough enfuvirtide (T-20) for only 12,000 people this year, 32,000 next year, citing difficulties in the manufacturing process

• Vertex Pharmaceuticals announces submission of NDA/MAA filings in US and Europe for amprenavir pro-drug (GW433908)

• BMS submits new drug application for investigational protease inhibitior atazanavir

• Europe and America approve once-a-day stavudine (d4T, Zerit)

• Tenofovir as HIV prevention: study to reduce HIV transmission in sexually active adults

• Boehringer chooses dose for phase III studies of tipranavir/ritonavir PI combination

Treatment access

• Lancet special report examines direction new WHO director general should take on several HIV/AIDS-related issues

Weight, diabetes, metabolic complications

• Adipose tissue alterations develop early in antiretroviral therapy

Basic science and immunology

• Breadth of memory CTL response against HIV associated with immune control

• Dendritic-cell vaccine elicits strong anti-SIV response in monkeys

• HIV infection causes fibrosis in lymphatic tissue, diminishing CD4+ pool

• Chronic immune activation: a lethal factor in HIV infection?

Other news

• Website run by a nun in a caravan is nominated for awards

• Infection by closely related HIV strains possible

On the web

• Report from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

• The science of side effects (or, who’s afraid of 3T3-F44A2 cells?)

• Medscape conference coverage, based on selected sessions at the 6th International Congress on Drug Therapy in HIV Infection

• 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

• T-20: a model for novel anti-HIV drugs in development

• Recent research in HIV infection: Part 1

• Medscape coverage: HIV/AIDS-related research at the 40th Annual Meeting of the Infectious Diseases Society of America

• HIV-associated sensory neuropathies

• New HIV Insite Knowledge Base chapters

• Protease inhibitor double boosting

• Historical essays from Science

• Treatment of primary HIV infection

• Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy

• Navigating resistance pathways

PDFs

• Volume 4 Number 1 January/February 2003 PDF